{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T10:59:33Z","timestamp":1788692373374,"version":"build-2803163510"},"reference-count":73,"publisher":"Jaypee Brothers Medical Publishing","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.59556\/japi.73.0844","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T07:49:02Z","timestamp":1746085742000},"page":"68-77","source":"Crossref","is-referenced-by-count":6,"title":["Association of Physicians of India Consensus Recommendations for Vonoprazan in Management of Acid Peptic Disorders"],"prefix":"10.59556","volume":"73","author":[{"given":"Rajesh","family":"Upadhyay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N K","family":"Soni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agam","family":"Vora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Saraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Haldipur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwaipayan","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwijen","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mangesh","family":"Tiwaskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milind","family":"Nadkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Arun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh B","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Bhadade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh R","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Bhargava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiran","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surya","family":"Kant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umesh","family":"Jalihal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"VG Mohan","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Kotamkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailesh","family":"Pallewar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Qamra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","reference":[{"issue":"(4):","key":"key20250501074859_B1","doi-asserted-by":"crossref","first-page":"358\u2013","DOI":"10.1016\/j.amjmed.2009.09.031","article-title":"Systematic review of the symptom burden, quality of life impairment and costs associated with peptic ulcer disease.","volume":"123","author":"Barkun","year":"2010;","journal-title":"Am J Med"},{"key":"key20250501074859_B2","doi-asserted-by":"crossref","first-page":"128.","DOI":"10.1186\/1477-7525-8-128","article-title":"Impact of gastroesophageal reflux disease on daily life: the Systematic Investigation of Gastrointestinal Diseases in China (SILC) epidemiological study.","volume":"8:","author":"Wang","year":"2010;","journal-title":"Health Qual Life Outcomes"},{"issue":"(1):","key":"key20250501074859_B3","doi-asserted-by":"crossref","first-page":"5814.","DOI":"10.1038\/s41598-020-62795-1","article-title":"Global prevalence and risk factors of gastro-oesophageal reflux disease (GORD): systematic review with meta-analysis.","volume":"10","author":"Nirwan","year":"2020;","journal-title":"Sci Rep"},{"issue":"(10):","key":"key20250501074859_B4","first-page":"69\u2013","article-title":"API-ISG consensus guidelines for management of gastroesophageal reflux disease.","volume":"68","author":"Bhatia","year":"2020;","journal-title":"J Assoc Physicians India"},{"issue":"(1):","key":"key20250501074859_B5","doi-asserted-by":"crossref","first-page":"e000350.","DOI":"10.1136\/bmjgast-2019-000350","article-title":"Risk factors of perioperative mortality from complicated peptic ulcer disease in Africa: systematic review and meta-analysis.","volume":"7","author":"Peiffer","year":"2020;","journal-title":"BMJ Open Gastroenterol"},{"key":"key20250501074859_B6","doi-asserted-by":"crossref","first-page":"E213\u2013","DOI":"10.2741\/Jones1","article-title":"Helicobacter pylori infection in peptic ulcer disease and gastric malignancy.","volume":"6:","author":"Jones","year":"2001;","journal-title":"Front Biosci"},{"issue":"(1):","key":"key20250501074859_B7","first-page":"99\u2013","article-title":"Multidisciplinary consensus for rationalizing the use of acid suppressants in children and adults: CONFOR.","volume":"14","author":"Prabhoo","year":"2024;","journal-title":"Euroasian J Hepatogastroenterol"},{"issue":"(1):","key":"key20250501074859_B8","doi-asserted-by":"crossref","first-page":"16\u2013","DOI":"10.4166\/kjg.2016.68.1.16","article-title":"The prevalence and clinical features of non-responsive gastroesophageal reflux disease to practical proton pump inhibitor dose in Korea: a multicenter study.","volume":"68","author":"Park","year":"2016;","journal-title":"Korean J Gastroenterol"},{"issue":"(3):","key":"key20250501074859_B9","doi-asserted-by":"crossref","first-page":"334\u2013","DOI":"10.3748\/wjg.15.334","article-title":"Prevalence of bile reflux in gastroesophageal reflux disease patients not responsive to proton pump inhibitors.","volume":"15","author":"Monaco","year":"2009;","journal-title":"World J Gastroenterol"},{"issue":"(6):","key":"key20250501074859_B10","doi-asserted-by":"crossref","first-page":"1047\u2013","DOI":"10.1046\/j.1365-2036.2002.01276.x","article-title":"Helicobacter pylori \u201crescue\u201d regimen when proton pump inhibitor-based triple therapies fail.","volume":"16","author":"Gisbert","year":"2002;","journal-title":"Aliment Pharmacol Ther"},{"issue":"(3):","key":"key20250501074859_B11","first-page":"113\u2013","article-title":"Proton pump inhibitors: prescribing practices, appropriateness of use, and cost incurred in a tertiary care, public, teaching hospital in New Delhi, India.","volume":"5","author":"Verma","year":"2019;","journal-title":"MAMC J Med Sci"},{"issue":"(4)","key":"key20250501074859_B12","first-page":"2\u2013","article-title":"Prospective assessment of prescribing pattern of intravenous proton pump inhibitors in an Indian tertiary-care teaching hospital.","volume":"7","author":"Churi","year":"2014;","journal-title":"Indian J Pharm Pract"},{"issue":"(4):","key":"key20250501074859_B13","first-page":"88\u2013","article-title":"An expert review and recommendations on the rational use of proton pump inhibitors: Indian perspective.","volume":"67","author":"Bhatia","year":"2019;","journal-title":"J Assoc Physicians India"},{"key":"key20250501074859_B14","article-title":"Office of Surveillance and Epidemiology (OSE) Epidemiology: ARIA Sufficiency Templates Version: 2018-01-24.","author":"Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research.","year":"2024."},{"key":"key20250501074859_B15","unstructured":"CDSCO Recommendations of the SEC (Gastroenterology & CDSCO Recommendations of the SEC (Gastroenterology &Hepatology) made in its 1st\/24 meeting held on 16.01.2024 & 17.01.2024 at CDSCO (HQ), New Delhi, India. Available from: https:\/\/cdsco.gov.in\/opencms\/opencms\/en\/Committees\/SEC\/."},{"issue":"(5):","key":"key20250501074859_B16","doi-asserted-by":"crossref","first-page":"796\u2013","DOI":"10.1111\/jgh.16475","article-title":"A systematic review meta-analysis of the efficacy of vonoprazan for proton pump inhibitor-resistant gastroesophageal reflux diseaseand.","volume":"39","author":"Simadibrata","year":"2024;","journal-title":"J Gastroenterol Hepatol"},{"key":"key20250501074859_B17","doi-asserted-by":"crossref","first-page":"534\u2013","DOI":"10.1111\/apt.15641","article-title":"Randomised trial of acid inhibition by vonoprazan 10\/20 mg once daily vs rabeprazole 10\/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH study).","volume":"51:","author":"Takeuchi","year":"2020;","journal-title":"Aliment Pharmacol Ther"},{"key":"key20250501074859_B18","doi-asserted-by":"crossref","first-page":"953.","DOI":"10.1186\/s12879-024-09885-x","article-title":"Efficacy and safety of vonoprazan-based treatment of Helicobacter pylori infection: a systematic review and network meta-analysis.","volume":"24:","author":"Huang","year":"2024;","journal-title":"BMC Infect Dis"},{"key":"key20250501074859_B19","doi-asserted-by":"crossref","first-page":"101401.","DOI":"10.1016\/j.mex.2021.101401","article-title":"Preparing, conducting, and analyzing Delphi surveys: cross-disciplinary practices, new directions, and advancements.","volume":"8:","author":"Beiderbeck","year":"2021;","journal-title":"MethodsX"},{"issue":"(2):","key":"key20250501074859_B20","doi-asserted-by":"crossref","first-page":"159\u2013","DOI":"10.1111\/his.14650","article-title":"Developing consensus in histopathology: the role of the Delphi method.","volume":"81","author":"Taze","year":"2022;","journal-title":"Histopathology"},{"key":"key20250501074859_B21","doi-asserted-by":"crossref","first-page":"541\u2013","DOI":"10.4300\/JGME-5-4-18","article-title":"Analyzing and interpreting data from Likert-type scales.","volume":"5:","author":"Sullivan","year":"2013;","journal-title":"J Grad Med Educ"},{"key":"key20250501074859_B22","doi-asserted-by":"crossref","first-page":"209\u2013","DOI":"10.1007\/s12664-020-01104-0","article-title":"Prevalence and risk factors for gastroesophageal reflux disease in the Indian population: a meta-analysis and meta-regression study.","volume":"40:","author":"Rai","year":"2021;","journal-title":"Indian J Gastroenterol"},{"issue":"(5):","key":"key20250501074859_B23","doi-asserted-by":"crossref","first-page":"411\u2013","DOI":"10.1007\/s12664-019-00979-y","article-title":"Indian consensus on gastroesophageal reflux disease in adults: a position statement of the Indian Society of Gastroenterology.","volume":"38","author":"Bhatia","year":"2019;","journal-title":"Indian J Gastroenterol"},{"issue":"(1):","key":"key20250501074859_B24","doi-asserted-by":"crossref","first-page":"15249.","DOI":"10.1038\/s41598-023-42636-7","article-title":"Risk factors and 26-years worldwide prevalence of endoscopic erosive esophagitis from 1997 to 2022: a meta-analysis.","volume":"13","author":"Witarto","year":"2023;","journal-title":"Sci Rep"},{"issue":"(5):","key":"key20250501074859_B25","doi-asserted-by":"crossref","first-page":"495\u2013","DOI":"10.1097\/00042737-200405000-00010","article-title":"Gastro-oesophageal reflux disease, reflux oesophagitis and non-erosive reflux disease in a multiracial Asian population: a prospective, endoscopy based study.","volume":"16","author":"Rosaida","year":"2004;","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"(9528):","key":"key20250501074859_B26","doi-asserted-by":"crossref","first-page":"2086\u2013","DOI":"10.1016\/S0140-6736(06)68932-0","article-title":"Gastro-oesophageal reflux disease.","volume":"367","author":"Moayyedi","year":"2006;","journal-title":"Lancet"},{"issue":"(3):","key":"key20250501074859_B27","doi-asserted-by":"crossref","first-page":"107\u2013","DOI":"10.1016\/j.gande.2024.03.001","article-title":"Refractory gastroesophageal reflux disease (GERD): a clinical, endoscopic, and histopathological perspective\u2014a single centre cross-sectional study.","volume":"2","author":"Verma","year":"2024;","journal-title":"Gastroenterol Endosc"},{"issue":"(7):","key":"key20250501074859_B28","doi-asserted-by":"crossref","first-page":"1151\u2013","DOI":"10.1111\/j.1440-1746.2011.06714.x","article-title":"Risk factors for Barrett\u2019s esophagus in Indian patients with gastroesophageal reflux disease.","volume":"26","author":"Mathew","year":"2011;","journal-title":"J Gastroenterol Hepatol"},{"issue":"(Suppl 2):","key":"key20250501074859_B29","doi-asserted-by":"crossref","first-page":"1877\u2013","DOI":"10.1007\/s12070-020-01882-1","article-title":"Prevalence of laryngopharyngeal reflux disease in Indian population.","volume":"74","author":"Mishra","year":"2022;","journal-title":"Indian J Otolaryngol Head Neck Surg"},{"issue":"(5):","key":"key20250501074859_B30","doi-asserted-by":"crossref","first-page":"517\u2013","DOI":"10.4103\/ijmr.IJMR_1482_16","article-title":"Prevalence of Helicobacter pylori infection & pattern of gastrointestinal involvement in patients undergoing upper gastrointestinal endoscopy in Sikkim.","volume":"147","author":"Dhakal","year":"2018;","journal-title":"Indian J Med Res"},{"issue":"(4):","key":"key20250501074859_B31","doi-asserted-by":"crossref","first-page":"559\u2013","DOI":"10.4103\/2141-9248.122109","article-title":"Prevalence of Helicobacter pylori infection among patients undergoing upper gastrointestinal endoscopy in a medical college hospital in Kerala, India.","volume":"3","author":"Adlekha","year":"2013;","journal-title":"Ann Med Health Sci Res"},{"issue":"(4):","key":"key20250501074859_B32","doi-asserted-by":"crossref","first-page":"605\u2013","DOI":"10.1053\/j.gastro.2023.12.022","article-title":"Global prevalence of Helicobacter pylori infection and incidence of gastric cancer between 1980 and 2022.","volume":"166","author":"Chen","year":"2024;","journal-title":"Gastroenterology"},{"issue":"(8):","key":"key20250501074859_B33","doi-asserted-by":"crossref","first-page":"1085.","DOI":"10.3390\/healthcare11081085","article-title":"Comparison of secular trends in peptic ulcer diseases mortality in China, Brazil and India during 1990\u20132019: an age-period-cohort analysis.","volume":"11","author":"Sun","year":"2023;","journal-title":"Healthcare"},{"issue":"(8):","key":"key20250501074859_B34","doi-asserted-by":"crossref","first-page":"656\u2013","DOI":"10.1016\/S1542-3565(04)00288-5","article-title":"Effectiveness of proton pump inhibitors in nonerosive reflux disease.","volume":"2","author":"Dean","year":"2004;","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"(9):","key":"key20250501074859_B35","doi-asserted-by":"crossref","first-page":"1340\u2013","DOI":"10.1136\/gutjnl-2011-301897","article-title":"Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors.","volume":"61","author":"Sifrim","year":"2012;","journal-title":"Gut"},{"key":"key20250501074859_B36","doi-asserted-by":"crossref","first-page":"446\u2013","DOI":"10.1097\/MAJ.0b013e31829f87d5","article-title":"Potential costs of inappropriate use of proton pump inhibitors.","volume":"347:","author":"Ladd","year":"2014;","journal-title":"Am J Med Sci"},{"issue":"(1):","key":"key20250501074859_B37","doi-asserted-by":"crossref","first-page":"25\u2013","DOI":"10.5056\/jnm.2013.19.1.25","article-title":"Pharmacokinetics and pharmacodynamics of the proton pump inhibitors.","volume":"19","author":"Shin","year":"2013;","journal-title":"J Neurogastroenterol Motil"},{"key":"key20250501074859_B38","doi-asserted-by":"crossref","first-page":"1309\u2013","DOI":"10.1046\/j.1365-2036.2002.t01-1-01281.x","article-title":"An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy.","volume":"16:","author":"Nzeako","year":"2002;","journal-title":"Aliment Pharmacol Ther"},{"key":"key20250501074859_B39","doi-asserted-by":"crossref","first-page":"654\u2013","DOI":"10.1080\/00365520701864635","article-title":"Relationship of severity of gastroesophageal reflux disease with gastric acid secretory profile and esophageal acid exposure during nocturnal acid breakthrough: a study using 24-h dual-channel pH-metry.","volume":"43:","author":"Ghoshal","year":"2008;","journal-title":"Scand J Gastroenterol"},{"key":"key20250501074859_B40","doi-asserted-by":"crossref","first-page":"447\u2013","DOI":"10.1080\/17425255.2018.1461835","article-title":"Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine.","volume":"14:","author":"El Rouby","year":"2018;","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"(10):","key":"key20250501074859_B41","doi-asserted-by":"crossref","first-page":"1473\u2013","DOI":"10.1111\/j.1365-2036.2006.02911.x","article-title":"Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease.","volume":"23","author":"Gunaratnam","year":"2006;","journal-title":"Aliment Pharmacol Ther"},{"issue":"(1):","key":"key20250501074859_B42","doi-asserted-by":"crossref","first-page":"158\u2013","DOI":"10.1007\/s10620-018-5235-9","article-title":"Optimal omeprazole dosing and symptom control: a randomized controlled trial (OSCAR trial).","volume":"64","author":"Waghray","year":"2019;","journal-title":"Dig Dis Sci"},{"issue":"(10S):","key":"key20250501074859_B43","doi-asserted-by":"crossref","first-page":"S342.","DOI":"10.14309\/01.ajg.0000951520.09659.d3","article-title":"S470 proton pump inhibitor dosing patterns are less than optimal among new referrals to an outpatient academic gastroenterology clinic.","volume":"118","author":"Adu-Gyamfi","year":"2023;","journal-title":"Am J Gastroenterol"},{"issue":"(4):","key":"key20250501074859_B44","doi-asserted-by":"crossref","first-page":"439\u2013","DOI":"10.1007\/s40265-015-0368-z","article-title":"Vonoprazan: first global approval.","volume":"75","author":"Garnock-Jones","year":"2015;","journal-title":"Drugs"},{"key":"key20250501074859_B45","unstructured":"Highlights of Prescribing Information. VOQUEZNA (Vonoprazan) Tablets, for Oral use Initial U.S. Approval: 2022. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=215151. [Accessed 28 November 2024]."},{"key":"key20250501074859_B46","unstructured":"PubChem. PubChem Compound Summary for CID 15981397, Vonoprazan. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Vonoprazan. [Accessed 28 November 2024]."},{"issue":"(7):","key":"key20250501074859_B47","doi-asserted-by":"crossref","first-page":"1158\u2013","DOI":"10.14309\/ajg.0000000000001735","article-title":"Pharmacodynamics and pharmacokinetics of the potassium-competitive acid blocker vonoprazan and the proton pump inhibitor lansoprazole in US subjects.","volume":"117","author":"Laine","year":"2022;","journal-title":"Am J Gastroenterol"},{"issue":"(6):","key":"key20250501074859_B48","doi-asserted-by":"crossref","first-page":"719\u2013","DOI":"10.1111\/apt.13325","article-title":"Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects\u2014a randomised open-label cross-over study.","volume":"42","author":"Sakurai","year":"2015;","journal-title":"Aliment Pharmacol Ther"},{"issue":"(2):","key":"key20250501074859_B49","doi-asserted-by":"crossref","first-page":"278\u2013","DOI":"10.1002\/cpdd.1009","article-title":"The effect of food on the pharmacokinetics of the potassium-competitive acid blocker Vonoprazan.","volume":"11","author":"Mulford","year":"2022;","journal-title":"Clin Pharmacol Drug Dev"},{"key":"key20250501074859_B50","doi-asserted-by":"crossref","first-page":"1228\u2013","DOI":"10.1053\/j.gastro.2024.06.038","article-title":"AGA clinical practice update on integrating potassium-competitive acid blockers into clinical practice: expert review.","volume":"167:","author":"Patel","year":"2024;","journal-title":"Gastroenterology"},{"issue":"(2):","key":"key20250501074859_B51","doi-asserted-by":"crossref","first-page":"174\u2013","DOI":"10.1159\/000497775","article-title":"Efficacy of vonoprazan, a novel potassium-competitive acid blocker, in patients with proton pump inhibitor-refractory acid reflux.","volume":"101","author":"Akiyama","year":"2020;","journal-title":"Digestion"},{"issue":"(11):","key":"key20250501074859_B52","doi-asserted-by":"crossref","first-page":"e19520.","DOI":"10.1097\/MD.0000000000019520","article-title":"Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease.","volume":"99","author":"Gotoh","year":"2020;","journal-title":"Medicine (Baltimore)"},{"issue":"(4):","key":"key20250501074859_B53","doi-asserted-by":"crossref","first-page":"267\u2013","DOI":"10.1007\/s00535-022-01861-z","article-title":"Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021.","volume":"57","author":"Iwakiri","year":"2022;","journal-title":"J Gastroenterol"},{"issue":"(1):","key":"key20250501074859_B54","doi-asserted-by":"crossref","first-page":"6\u2013","DOI":"10.5056\/jnm.2014.20.1.6","article-title":"New and future drug development for gastroesophageal reflux disease.","volume":"20","author":"Maradey-Romero","year":"2014;","journal-title":"J Neurogastroenterol Motil"},{"issue":"(6):","key":"key20250501074859_B55","doi-asserted-by":"crossref","first-page":"439\u2013","DOI":"10.1177\/1756283X17705329","article-title":"A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis.","volume":"10","author":"Iwakiri","year":"2017;","journal-title":"Therap Adv Gastroenterol"},{"issue":"(1):","key":"key20250501074859_B56","doi-asserted-by":"crossref","first-page":"61\u2013","DOI":"10.1053\/j.gastro.2022.09.041","article-title":"Vonoprazan versus lansoprazole for healing and maintenance of healing of erosive esophagitis: a randomized trial.","volume":"164","author":"Laine","year":"2023;","journal-title":"Gastroenterology"},{"key":"key20250501074859_B57","first-page":"CD002095.","article-title":"Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.","volume":"5:","author":"Sigterman","year":"2013;","journal-title":"Cochrane Database Syst Rev"},{"key":"key20250501074859_B58","doi-asserted-by":"crossref","first-page":"1016\u2013","DOI":"10.1111\/apt.17728","article-title":"Randomised clinical trial: efficacy and safety of on-demand vonoprazan versus placebo for non-erosive reflux disease.","volume":"58:","author":"Fass","year":"2023;","journal-title":"Aliment Pharmacol Ther"},{"issue":"(11):","key":"key20250501074859_B59","doi-asserted-by":"crossref","first-page":"2211\u2013","DOI":"10.1016\/j.cgh.2024.05.004","article-title":"Vonoprazan is efficacious for treatment of heartburn in non-erosive reflux disease: a randomized trial.","volume":"22","author":"Laine","year":"2024;","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key20250501074859_B60","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.8598.1","article-title":"The role of acid inhibition in Helicobacter pylori eradication.","volume":"5:","author":"Scott","year":"2016;","journal-title":"F1000Res"},{"issue":"(9):","key":"key20250501074859_B61","doi-asserted-by":"crossref","first-page":"1730\u2013","DOI":"10.14309\/ajg.0000000000002968","article-title":"ACG clinical guideline: treatment of Helicobacter pylori infection.","volume":"119","author":"Chey","year":"2024;","journal-title":"Am J Gastroenterol"},{"key":"key20250501074859_B62","first-page":"382\u2013","article-title":"Recurrence of Helicobacter pylori infection and duodenal ulcer relapse, following successful eradication in an urban east Asian population.","volume":"41:","author":"Khor","year":"2000;","journal-title":"Singapore Med J"},{"issue":"(2):","key":"key20250501074859_B63","doi-asserted-by":"crossref","first-page":"715\u2013","DOI":"10.22207\/JPAM.13.2.07","article-title":"Helicobacter pylori infection: challenges in India.","volume":"13","author":"Singh","year":"2019;","journal-title":"J Pure Appl Microbiol"},{"issue":"(6):","key":"key20250501074859_B64","doi-asserted-by":"crossref","first-page":"1042\u2013","DOI":"10.1136\/gutjnl-2017-314010","article-title":"Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study.","volume":"67","author":"Mizokami","year":"2018;","journal-title":"Gut"},{"issue":"(5):","key":"key20250501074859_B65","doi-asserted-by":"crossref","first-page":"425\u2013","DOI":"10.1080\/14740338.2023.2136163","article-title":"Long-term safety and effectiveness of vonoprazan for prevention of gastric and duodenal ulcer recurrence in patients on nonsteroidal anti-inflammatory drugs in Japan: a 12-month post-marketing surveillance study.","volume":"22","author":"Kawai","year":"2023;","journal-title":"Expert Opin Drug Saf"},{"issue":"(4):","key":"key20250501074859_B66","first-page":"266\u2013","article-title":"Vonoprazan in the management of gastric\/peptic ulcers: a systematic review of safety data.","volume":"17","author":"Moraes-Filho","year":"2022;","journal-title":"Prz Gastroenterol"},{"issue":"(6):","key":"key20250501074859_B67","doi-asserted-by":"crossref","first-page":"936\u2013","DOI":"10.1016\/j.otohns.2007.08.011","article-title":"Dosing of proton pump inhibitors is suboptimal among otolaryngologists treating reflux-induced upper-respiratory disease.","volume":"137","author":"Humayun","year":"2007;","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"(11):","key":"key20250501074859_B68","first-page":"1323\u2013","article-title":"The preliminary application of vonoprazan fumarate on laryngopharyngeal reflux disease.","volume":"57","author":"Han","year":"2022;","journal-title":"Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi"},{"issue":"(2):","key":"key20250501074859_B69","doi-asserted-by":"crossref","first-page":"191\u2013","DOI":"10.4168\/aair.2024.16.2.191","article-title":"Potassium-competitive acid blocker versus proton pump inhibitor: a pilot study on comparable efficacy in the treatment of gastroesophageal reflux-related cough.","volume":"16","author":"Zhong","year":"2024;","journal-title":"Allergy Asthma Immunol Res"},{"key":"key20250501074859_B70","first-page":"S1542.","article-title":"Vonoprazan as a long-term maintenance treatment for erosive esophagitis: VISION, a 5-year, randomized, open-label study.","author":"Uemura","year":"2024:","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"(4):","key":"key20250501074859_B71","doi-asserted-by":"crossref","first-page":"778\u2013","DOI":"10.1053\/j.gastro.2024.03.036","article-title":"Comparison of vonoprazan versus intravenous proton pump inhibitor for prevention of high-risk peptic ulcers rebleeding after successful endoscopic hemostasis: a multicenter randomized noninferiority trial.","volume":"167","author":"Geeratragool","year":"2024;","journal-title":"Gastroenterology"},{"issue":"(12):","key":"key20250501074859_B72","doi-asserted-by":"crossref","first-page":"e0261703.","DOI":"10.1371\/journal.pone.0261703","article-title":"Efficacy of vonoprazan against bleeding from endoscopic submucosal dissection-induced gastric ulcers under antithrombotic medication: a cross-design synthesis of randomized and observational studies.","volume":"16","author":"Hidaka","year":"2021;","journal-title":"PLoS One"},{"issue":"(1):","key":"key20250501074859_B73","doi-asserted-by":"crossref","first-page":"51\u2013","DOI":"10.1016\/j.jjcc.2020.02.012","article-title":"Upper gastrointestinal bleeding in Japanese patients with ischemic heart disease receiving vonoprazan or a proton pump inhibitor with multiple antithrombotic agents: a nationwide database study.","volume":"76","author":"Tsujita","year":"2020;","journal-title":"J Cardiol"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T07:49:13Z","timestamp":1746085753000},"score":1,"resource":{"primary":{"URL":"https:\/\/japi.org\/article\/japi-73-2-68"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.59556\/japi.73.0844"],"URL":"https:\/\/doi.org\/10.59556\/japi.73.0844","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}